Welcome to Vayuna Therapeutics
Vayuna Therapeutics is developing precision medications derived from nature's most potent plants to target treatment-resistant cancers within genomically defined patient populations
FIRST-IN-CLASS
Next-Generation Precision
ADCs and Parenteral Formulations with V-001
for PIK3CA-Mutated and
Treatment-Resistant Cancers
THE PROBLEM
Treatment Resistance in Cancer
Limited effective therapies for treatment-resistant solid tumors.
PIK3CA mutations drive resistance in ~40% of HR+ breast cancers leading to excessive PI3K signaling activation and treatment resistance.
Existing treatments are imprecise, resulting in suboptimal outcomes and significant toxicity.
the solution
Superior Efficacy
V-001 outperforms standards of care in NCI-60 screen, targeting PIK3CA-mutated and resistant cancers
HER-2/EGFR-directed ADCs
Precision delivery of V-001 payload for enhanced therapeutic effect.
Parenteral Formulations:
Systemic treatment for advanced & metastatic PIK3CA-mutated cancers.
Biomarker-Driven
Precision targeting for better outcomes, reduced toxicity and personalized care.
